P.C. Giordano et al. A confidential inquiry estimating the number of patients affected with sickle cell disease and thalassemia major confirms the need for a preventive strategy in the Netherlands. hemoglobin (2004),28: 287-296

In a period of 2 years an unselected group of pregnant females (n = 1000) and a group of newborns (n = 1000) will be screened for hemoglobinopathies.
Primary endpoint is the carrier frequence of hemoglobinopathies, secondary endpoints are the compliance to prenatal testing, iron stores and cost-effectiveness.